TI
CRVS icon

Telemetry Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

Telemetry Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$332K Sell
390,000
-132,009
-25% -$117K 0.78% 50
2022
Q3 		$427K Buy
522,009
+61,906
+13% +$59.1K 0.7% 55
2022
Q2 		$456K Buy
460,103
+172,603
+60% +$212K 0.7% 57
2022
Q1 		$472K Buy
287,500
+94,591
+49% +$173K 0.76% 51
2021
Q4 		$465K Sell
192,909
-3,259
-2% -$12.6K 0.61% 56
2021
Q3 		$949K Sell
196,168
-67,807
-26% -$201K 1.3% 21
2021
Q2 		$705K Buy
263,975
+14,969
+6% +$41.2K 0.98% 36
2021
Q1 		$767K Buy
249,006
+59,925
+32% +$216K 0.87% 42
2020
Q4 		$673K Buy
+189,081
New +$761K 1.24% 33
2019
Q3 		– Sell
-101,218
Closed -$379K – 57
2019
Q2 		$379K Sell
101,218
-48,981
-33% -$192K 0.76% 55
2019
Q1 		$604K Buy
150,199
+15,076
+11% +$63.6K 1.21% 47
2018
Q4 		$496K Buy
+135,123
New +$921K 0.66% 75
2017
Q4 		– Sell
-27,000
Closed -$430K – 142
2017
Q3 		$430K Buy
+27,000
New +$374K 0.44% 77

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return